Trial Profile
A study to assess the efficacy and safety of sofosbuvir and daclatasvir in HIV/HCV co-infected patients with advanced fibrosis.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 24 Aug 2015 Status changed from completed to recruiting as per both the results i.e presented at the meeting "50th Annual Meeting of the European Association for the Study of the Liver" and "22nd Conference on Retroviruses and Opportunistic Infections" are interim and final results with primary efficacy endpoints will be presented in future.
- 10 Aug 2015 New trial record